DrugPatentWatch Database Preview
Drugs in Development Information for HGP0904
» See Plans and Pricing
What is the development status for investigational drug HGP0904?
HGP0904 is an investigational drug.
There have been 7 clinical trials for HGP0904.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 16th 2019.
The most common disease conditions in clinical trials are Hypertension, Dyslipidemias, and Erectile Dysfunction. The leading clinical trial sponsors are Hanmi Pharmaceutical Company Limited, Seoul National University Bundang Hospital, and [disabled in preview].
There are two US patents protecting this investigational drug and twenty-nine international patents.
Summary for HGP0904
| US Patents | 2,485 |
| International Patents | 29,243 |
| US Patent Applications | 4,618 |
| WIPO Patent Applications | 2,800 |
| Japanese Patent Applications | 27 |
| Clinical Trial Progress | Phase 3 (2019-07-16) |
| Vendors | 78 |
Recent Clinical Trials for HGP0904
| Title | Sponsor | Phase |
|---|---|---|
| A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia | Hanmi Pharmaceutical Company Limited | Phase 3 |
| A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination and Co-Administration of HGP0904, HGP0608 and HCP1306 Tablets in Healthy Male Subjects. | Hanmi Pharmaceutical Company Limited | Phase 1 |
| A Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interactions Between HGP0904, HGP0608, and HCP1306 in Healthy Male Subjects. | Hanmi Pharmaceutical Company Limited | Phase 1 |
Clinical Trial Summary for HGP0904
Top disease conditions for HGP0904
Top clinical trial sponsors for HGP0904
US Patents for HGP0904
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| HGP0904 | Start Trial | Combination therapy | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) | Start Trial |
| HGP0904 | Start Trial | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | Start Trial |
| HGP0904 | Start Trial | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | Reset Therapeutics, Inc. (South San Francisco, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for HGP0904
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| HGP0904 | Australia | 2011249722 | 2030-05-05 | Start Trial |
| HGP0904 | Brazil | 112012028136 | 2030-05-05 | Start Trial |
| HGP0904 | Canada | 2797310 | 2030-05-05 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
